within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX21_Serelaxin;

model Serelaxin
  extends Pharmacolibrary.Drugs.ATC.C.C01DX21;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01DX21</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Serelaxin is a recombinant form of human relaxin-2, a hormone involved in the cardiovascular and renal adaptive changes during pregnancy. It has been developed as a treatment for acute heart failure but is not approved for use by regulatory agencies as of 2024.</p><h4>Pharmacokinetics</h4><p>PK parameters reported in patients with acute heart failure following 48-hour intravenous infusion.</p><h4>References</h4><ol><li><p>Kobalava, Z, et al., &amp; Halabi, A (2015). Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. <i>British journal of clinical pharmacology</i> 79(6) 937–945. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12572&quot;>10.1111/bcp.12572</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25511105/&quot;>https://pubmed.ncbi.nlm.nih.gov/25511105</a></p></li><li><p>Dahlke, M, et al., &amp; Pang, Y (2016). Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study. <i>Journal of clinical pharmacology</i> 56(4) 474–483. DOI:<a href=&quot;https://doi.org/10.1002/jcph.607&quot;>10.1002/jcph.607</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26239266/&quot;>https://pubmed.ncbi.nlm.nih.gov/26239266</a></p></li><li><p>Soubret, A, et al., &amp; Dahlke, M (2018). Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects. <i>British journal of clinical pharmacology</i> 84(11) 2572–2585. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13714&quot;>10.1111/bcp.13714</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30014598/&quot;>https://pubmed.ncbi.nlm.nih.gov/30014598</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Serelaxin;
